Trial Profile

A phase 2/3 Pivotal Trial to Evaluate AGTC-501 in X-Linked Retinitis Pigmentosa (XLRP)

Status: Recruiting

Phase of Trial: Phase II/III

Latest Information Update: 14 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

12 Jun 2024 According to Beacon Therapeutics media release, the company plans to use the data generated from the VISTA trial, in combination with data from the Phase 1/2 HORIZON and Phase 2 SKYLINE studies, including all available long-term data, to support a BLA in the US and a MAA in Europe for the treatment of patients with XLRP.
12 Jun 2024 According to Beacon Therapeutics media release, additional sites expected to open in multiple countries.
12 Jun 2024 According to Beacon Therapeutics media release, the company announced the treatment of the first patient in its registrational VISTA clinical trial with AGTC-501 (laruparetigene zovaparvovec).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com